Systemic SC dosing is reserved for recovery blocks and whole-body anti-inflammatory use, where the tissue-signaling effects outlast the peptide's time in plasma
References: Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial Conducted in the USA
Skin feels soft and refreshed after each use
These clinicians evaluate your complete health picture and determine whether medication may be appropriate for your situation
GHK-Cu acts via dermal papilla stem cells and matrix
If the pattern follows other incretin therapies, weight regain after cessation is likely